Cytovale Inc. has posted a feverish run of wins lately. The company gained U.S. FDA clearance for its Intellisep rapid test for sepsis in January 2023, raised $84 million in a series C in November and ...

In the wake of Novo Nordisk’s semaglutide nabbing the title of the U.S.’s biggest blockbuster drug, it’s little surprise that Amgen Inc.’s obesity candidate, Maritide (maridebart cafraglutide), hogged ...

Japanese researchers have transplanted human induced pluripotent stem cells (iPSCs) in a primate model of myocardial infarction and were able to restore heart muscle and function in monkeys. Developed ...

Quest Diagnostics Inc. and Pathai Inc. established a forward-looking deal with multiple components and room for growth. The ...

Novartis AG is bolstering its radioligand arsenal with the takeout of Mariana Oncology Inc. for $1 billion up front and as ...

Eluminex Biosciences Ltd. announced the FDA’s acceptance of their IND application for EB-105, a trispecific fusion antibody targeting vascular endothelial growth factor A (VEGF-A, and isomers), VEGF-B ...

Lindis Blood Care GmbH recently revealed excellent data from the Remove study that showed that its Catuvab device was safe and effective in removing tumor cells from intraoperative blood during high ...

South Korea’s HK Inno.N Corp. said on May 2 that it gained exclusive development and commercial rights to Hangzhou, China-based Sciwind Biosciences Co. Ltd.’s once-weekly, injectable glucagon-like ...

Medtronic plc said it secured U.S. FDA approval for its first closed-loop spinal cord stimulator (SCS), designed to take in ...

Novartis AG is acquiring Mariana Oncology Inc. for $1 billion up front and as much as $750 million in potential milestone payments. Watertown, Mass.-based Mariana has developed a portfolio of ...

Vedanta Biosciences Inc. has been awarded $3.9 million in funding from the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to advance its VE-707 preclinical development ...

Achieving proof of concept and a substantial clinical benefit with its PARP inhibitor stenoparib in advanced recurrent ovarian cancer, Allarity Therapeutics Inc. stopped a phase II trial and is ...